NASDAQ · VCRE

Vicore Pharma Holding AB American

$11.38 -$0.01 (-0.09%) 1D Market open
Charting by TradingView

Key Metrics

$320.66M
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM —
Dividend yield —
Free cash flow —
Beta · 1Y —
EBITDA · TTM —
Gross margin —

Snapshot

Market cap$320.66M
Enterprise value—
Shares outstanding28.2M
52-wk range$11.00 – $17.80
Avg volume · 20D59.5K
Net cash —
Book value / share—
ExchangeNASDAQ
About Vicore Pharma Holding AB American
IPO dateJul 2, 2026
Employees—

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net —
FCF —
ROE / ROIC — · —

Financial Health

Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital—

Cash Flow · TTM

Operating CF —
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

—
Needs two fiscal years of filings

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value